Advertisement
U.S. markets open in 9 minutes
  • S&P Futures

    5,308.50
    +0.25 (+0.00%)
     
  • Dow Futures

    40,179.00
    +35.00 (+0.09%)
     
  • Nasdaq Futures

    18,500.50
    -3.25 (-0.02%)
     
  • Russell 2000 Futures

    2,141.30
    +2.90 (+0.14%)
     
  • Crude Oil

    82.46
    +1.11 (+1.36%)
     
  • Gold

    2,232.50
    +19.80 (+0.89%)
     
  • Silver

    24.77
    +0.02 (+0.07%)
     
  • EUR/USD

    1.0811
    -0.0019 (-0.17%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • Vix

    12.96
    +0.18 (+1.41%)
     
  • GBP/USD

    1.2635
    -0.0003 (-0.02%)
     
  • USD/JPY

    151.3350
    +0.0890 (+0.06%)
     
  • Bitcoin USD

    70,619.70
    -507.18 (-0.71%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,954.96
    +22.98 (+0.29%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

iBio Expands Immuno-Oncology Pipeline With RubrYc Deal

  • iBio Inc (NYSE: IBIO) has signed an exclusive license agreement with RubrYc Therapeutics Inc for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs).

  • Related: IBio Adds Three Cancer Antibody Programs.

  • iBio plans to use its development and manufacturing capabilities to advance anti-CD25 antibody RTX-003 as IBIO-101 in the Phase 1 trial.

  • Initiation of IND-enabling studies is expected by mid-2022.

  • The partnership also includes an option agreement for iBio to license additional antibodies built using RubrYc's artificial intelligence-based antibody discovery platform.

  • As part of the agreements, iBio paid $5 million upfront, with an additional $2.5 million commitment for December 2021. iBio will also acquire an equity stake in RubrYc.

  • RubrYc is eligible to receive certain pre-specified payments upon achievement of development milestones for IBIO-101, as well as royalties on net sales of that molecule and other licensed antibodies.

  • Price Action: IBIO shares are up 1.98% at $1.28 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement